Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

With the price having reached EVO's stingy target of 26p it was only fair of them to update to a new stingy target. Still 36p will do for starters.

Perhaps a trading update is now less likely?

Here's a taster for the full report go to EVO Website
2006 holds much promise


2006 stands to be a strong year for Osmetech. Management has built a strong
product pipeline, which should drive a strong start to 2006 with the anticipated
1H06 launches of OPTI GENE, OPTI TUBE and Thrombosis Risk Marker tests and
the eSensor and cystic fibrosis test. The company has stoked interest in its initial
molecular diagnostics offering in the lead up to their 1H06 launch at the
November 2005 AMP and Medica industry meetings as evidenced from the
positive reception. In addition, the full period impacts of previous launches with
their attractive recurring consumable stream will further drive performance.

Very positive trading statement out this am. OMH is positive FDA approval on CF eSensor test will be concluded within weeks.

Full text
http://moneyam.uk-wire.com/cgi-bin/articles/200601190700161246X.html

How long before we reach the EVO target this time? The last couple of EVO targets were reached within in a couple of weeks of them announcing it.

"We are confident of receiving FDA approval for its eSensor instrument and cystic fibrosis (CF) test within the next few weeks, which would be a first for a combined instrument and consumable CF assay."

If this happens in the next couple of weeks 36p will be passed at the speed of light

More to the point whats NEW ADVISER Hoare Govett's target going to be??

A good move getting rid of EVO as their reputation alone would deter some investors.

FDA Approval Granted!

EXCELLENT NEWS

FDA approval

RNS Number:3456X
Osmetech PLC
24 January 2006

24 January 2006


Osmetech plc receives FDA clearance for its cystic fibrosis molecular
diagnostics test


Osmetech plc, the international healthcare diagnostics group, has received its
510(k) clearance from the US Food & Drug Administration ('FDA') for its cystic
fibrosis ('CF') carrier detection test and its eSensorTM4800 DNA Detection
instrument platform. Sales of the instrument and CF test will commence in the
first half of 2006 as planned.


James White, CEO Osmetech plc said, 'Gaining FDA clearance for our first
microarray based test developed for our new eSensorTM molecular diagnostics
instrument is a major step forward for our Molecular Diagnostics Division and
will help to establish Osmetech as a key player in the fast growing molecular
diagnostics market. In addition, this FDA clearance helps to validate our
microarray technology for routine use in the laboratory.


'Following the approval of the eSensorTM platform we now look forward to
progressing discussions with strategic partners who are looking for cost
effective and easy to use instrumentation and consumables to work on other
complex assays both in the healthcare and non healthcare markets. The next
Osmetech Molecular test targeted for FDA submission will be our CYP 450
pharmacogenomics assay, which is currently in development.'


Background information on Cystic Fibrosis

With a carrier frequency of one in 25 and an incidence of one in 2,500, Cystic
Fibrosis is the most commonly inherited disease in the North American Caucasian
population. The American College of Medical Genetics and the American College of
Obstetricians and Gynaecologists recommended in 2001 that Cystic Fibrosis
carrier testing should be made available for all reproductive couples. Currently
around one million tests are carried out annually in the US alone.


Most current tests are not FDA approved and testing locations are restricted to
those 300 institutions which are CLIA approved for running complex testing where
the testing institution is responsible for regulatory obligations rather than
the diagnostic company. The tests carried out in the large central laboratories
are performed on instruments that can cost in the region of US$100,000 and a
high throughput is required to justify the capital cost of the equipment. In
addition the instruments are operated by qualified technicians capable of
interpreting the results. As a result of this each test is relatively expensive
with each test recharged at up to US$400 per test to those small to medium sized
hospitals requesting the tests to be run on their behalf.



Ends


Enquiries:
Osmetech plc: James White/David Sandilands 020 7849 6027
Madano Partnership: Matthew Moth/Mark Way 020 7593 4000




Notes to editors:

Background on the Molecular Diagnostics Market

Molecular diagnostics is the fastest growth segment of the global diagnostics
market with annual growth rates in excess of 20%.

The benefits of molecular diagnostics are that it can provide highly accurate
testing, the possibility of earlier detection of infectious diseases and can
identify patients with a predisposition for certain diseases such as cystic
fibrosis and certain cancers. This provides the facility for earlier
intervention of therapy thereby facilitating improved treatment success rates.

Molecular diagnostics can also enable physicians to pre-determine drug dosages
and monitor the effectiveness of such treatments for individual patients and
also aid the avoidance of toxicity or adverse drug reactions.



The two main growth drivers for the molecular diagnostics market are the Human
Genome Project and the growth of new technologies providing the opportunity for
small and medium sized hospitals to carry out tests within this market. Through
the Human Genome Project, over 30,000 genes have been sequenced. Assuming that 5
per cent. of these genes will be of diagnostic significance this would create
1,500 gene based tests.



The molecular diagnostics market today is at an early stage of development and
is characterised by expensive first generation instruments which require skilled
labour and are reliant on high throughput in order to control costs. The batch
testing performed in large laboratories and hospitals precludes the ability to
give rapid turnaround times. Whilst the common PCR technology is widely
understood Osmetech believes that the products available today do not meet the
needs of small and medium sized hospitals.



Three main sub segments account for over 75 per cent. of the US molecular
diagnostics market: Human Genetics, Pharmacogenomics and Infectious Diseases.



Human genetics focuses on enabling the physician to test individuals for
diseases for which they have a genetic predisposition, for example: cystic
fibrosis, thrombosis, Alzheimer's or certain cancers. This is achieved through
the detection of SNPs or "mistakes" in an individual's DNA which may cause the
mutations that are associated with a particular disease. This is the segment
where Osmetech is launching its first products.




This information is provided by RNS
The company news service from the London Stock Exchange
END

REAIIFIALDISFIR

Minor treeshake today. Good buying opertunity IMO

Motorola, have sold their shares in the Company (212,470,862 pre consolidation so now 21,247,086) but only got 20p each for them. 6 months to the day the earlyest they could sell them.
Exact number of the big trade today.
Buy early these will go up friday.

Good prognosis

Keep an eye on healthcare diagnostics group Osmetech. That was the word among market professionals last night after a large stock overhang was cleared. Evolution Securities placed 21m shares - around 16% of the company - at 20p on behalf of Motorola with a variety of City institutions and private client brokers. Motorola's shareholding dates back to the summer when it sold its Clinical Micro Sensors business to Osmetech. With the Motorola holding out of the way, traders were expecting the stock to rally this morning. Earlier this week Osmetech, which recently appointed Hoare Govett as its broker, received American regulatory clearance for its cystic fibrosis carrier detection test. Yesterday Osmetech shares lost 4.5p, or 14.5%, to close at 26.25p.

In other words everything is on track and dont be panicked into selling!

From todays RNS
Osmetech has no further information to add to its Trading Update of 19 January
2006 and the FDA clearance of the CMS eSensor cystic fibrosis test announced on
24 January 2006.

Ends

Double post

The Latest Wallstreet Reporter Interview with Jame White (Thanks to DP)

Osmetech firmed 0.75p to 24.5p amid talk that testing of its cystic fibrosis diagnostics kit is ahead of schedule.

Just announced.

Osmetech Plc Notice of Results
RNS Number:8280Y
Osmetech PLC
23 February 2006



Notification of Final Results announcement



Osmetech, the international medical devices and diagnostics group, is to
announce its preliminary results for the 8 months to 31 December 2005 on Tuesday
21st March 2006.



As previously announced, Osmetech has now changed to a December financial year
end. As a result there was no interim results statement for the 6 months ended
31 October 2005.



Enquiries:

Mark Way

madano partnership 020 7593 4000

Last time we had a months notice of the results was the 30 June 2003.
The price on that date was 32p. The price dropped initially to 29p on the 2nd July before recovering and hitting a peak of 50p on the 28th July.

By the time of the results on the 30 July 2003 the price had fallen back to 43p.

I made sh1t loads of money that month!

Bring it on this time!

Bangers are you running a challenge here?

Well here's the price predictions from the OMH thread on a competitors site. If there's any Osmetech share holders here that would like to join in the just post your price guess for the EOD price on the day before the results - 20th March 2006. Competition closes 16:30 today.

Guess the price EOD on the 20th Mar 06. Current Average Guess = 35.5p!!

Poster's Name Price Youcorksuckers 48p JamesDean 43.2p Tradingplenty 43p Galco 41.5p Bangers 40p Ditchpig 39.75p Bucketfull 39p Muffster 39p CHESTERONE 38.75p bcfcruleok 38.25p Canaries 38p bleunose 37.5p cricketmad 37.5p Freddyfrog 37p eurojaws 36.75p Biofish 36.5p boonyed 36.5p REDHILL 36p Protec 35.5p Jacinta 34.5p tanchos 34.25p Gerry2 34p troutisout 33.5p Hutchmeister 33p BennyTheBall 33p sequoia 33p The Explorer 32.5p lomac 31.5p Rosco 29.5p The Novice 29p PC 27.75p C Moggie 27p HoT 20p

Looks good to me. I've tipped at 39.75p though that might be a little conservative now.

Just a quick glance back over the historic chart patterns shows that OMH can and does make some huge moves prior to the results. Rises of 50 -75% have been seen in a space of the few weeks prior to the figures release.

Interestingly a poster on ADVFN has estimated that the takeout value of Osmetech could be in the region of 500m or about 3.80 a share.
That's based on the value Becton Dickinson paid for GeneOhm at 46x revenues purely revenues from their PCR buisness of $5 million. Osmetech revenues from the blood gas critical care side of the buisness already exceed $5 million and with the imminent launch of OPTIgene and eSensor Osmetech group revenues are expected to greatly exceed that figure very rapidly.